Novartis reported $202M in Interest Expense on Debt for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Amgen AMGN:US $ 296M 15M
Aphria Inc APH:CN C$ 10.45M 3.97M
Biogen BIIB:US $ 66.3M 9.9M
Bristol Myers Squibb BMY:US $ 328M 2M
Catalent CTLT:US $ 26M 5.9M
Eli Lilly And LLY:US $ 83.6M 3.3M
Endo International Ordinary Shares ENDP:US $ 142.99M 1.35M
Gilead Sciences GILD:US $ 250M 6M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
JAZZ PHA JAZZ:US $ 93.47M 23.65M
Lannett LCI:US $ 14.22M 1.01M
Novartis NOVN:VX 202M 1000K
Pacira Pharmaceuticals PCRX:US $ 7.33M 0.31M
Pfizer PFE:US $ 325M 9M
Phibro Animal Health PAHC:US $ 3.06M 0.03M
Prestige Brands PBH:US $ 16.31M 1.24M
Supernus Pharmaceuticals SUPN:US $ 5.92M 1.43M
Teva Pharmaceutical Industries TEVA:US $ 232M 8M
Valeant Pharmaceuticals VRX:CN $ 357M 12M
Zoetis ZTS:US $ 56M 1M